Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CereKin
- Development stage
- Discontinued
- Lead developer
- Elanco
- Administration
- Injectable
01
Overview
**CereKin (KB010)** is a biologic interleukin-1 (IL-1) inhibitor developed by Kindred Biosciences for veterinary use in dogs. It was investigated as an injectable therapy to control pain and inflammation associated with **osteoarthritis** in canine patients. The drug aimed to block IL-1 signaling, a key pro-inflammatory cytokine implicated in joint degeneration and pain in osteoarthritis, but its pivotal field study failed to meet the primary endpoint, leading to discontinuation of the program.
02
Targets
IL1A (Interleukin 1 alpha)
Beyond the preview
Go deeper on CereKin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CereKin.